proteomic changes upon treatment with semaglutide in individuals with obesity Semaglutide-Mediated Remodeling of Adipose Tissue Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control Proteomic signatures reflect effects of

UTIs in Special Populations Urinary Tract Infections dont affect everyone the same way

GLP-1Rs are not only widely expressed in the central nervous system but also in peripheral nerves such as vagal afferents

The 24-well plates were incubated with the resazurin solution for 4 h to measure cell viability

Key drivers behind GLP-1 and addiction research include: Rapid expansion in the use of GLP-1 medications such as semaglutide (Ozempic and Wegovy) and tirzepatide (Maunjaro and Zepbound) Reports of changes in cravings, alcohol use, or reward-seeking behaviors beyond weight loss Increased public conversation and clinical curiosity about psychological and behavioral effects Scientific interest in GLP-1 activity within reward pathways and dopamine signaling Recognition that appetite regulation and addiction involve shared neural mechanisms This research is still emerging, and findings should be interpreted with caution

He L, Feng D, Guo H, et al

The platform is built on the premise that womens health conditions dont exist in isolation